Biodesix vs Exagen
BDSX and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDSX and XGN compare
Biodesix and Exagen are about the same size, with market caps of $107M and $122M.
Biodesix grew revenue faster over the last twelve months (31.2% versus 13.7% for Exagen).
Exagen keeps more of each dollar of sales as profit, with a net margin of −25.1% compared with −25.7% at Biodesix.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDSX | XGN |
|---|---|---|
| Size and price | ||
| Market cap | $107M | $122M |
| Share price | $10.12 | $5.04 |
| Change, 1 year | 34.2% | −46.8% |
| Change, 5 years | −92.1% | −58.4% |
| Beta (5Y) | 0.73 | 1.21 |
| Employees | 334 | 220 |
| StockData Score | ||
| Total score | 4 | 4 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.0× (better) | 1.7× |
| P/B | 12.3× | 8.9× (better) |
| FCF yield | −17.9% | −10.7% (better) |
| Fair value | – | $3.68 |
| Margin of safety | – | −36.7% |
| Growth | ||
| Revenue growth (TTM) | 31.2% (better) | 13.7% |
| Revenue growth, 5Y average | 14.2% (better) | 9.7% |
| Profitability | ||
| Gross margin | – | 58.7% |
| Operating margin | −18.7% (better) | −20.1% |
| Net margin | −25.7% | −25.1% (better) |
| FCF margin | −18.1% | −18.0% (better) |
| Return on equity | −779% | −114% (better) |
| Return on invested capital | −55.4% (better) | −167% |
| Financial health | ||
| Debt / equity | 5.43 | 1.66 (better) |
| Interest coverage | −2.5× (better) | −2.9× |
| Current ratio | 2.96 | 3.46 (better) |
| Altman Z-score | −6.23 | −5.39 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −30.7% | – |
| Shareholder yield | −30.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 41.4% | 34.1% |
| Held by insiders | – | 29.2% |
| Insider net buying, 12 months | $3.0M (better) | −$396K |
| Short interest, % of float | – | 4.2% |
Go deeper
- BDSX stock overview
- BDSX income statement
- BDSX valuation and score
- XGN stock overview
- XGN income statement
- XGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.